CA2404688C - Nuclear factor .kappa.b inducing factor - Google Patents

Nuclear factor .kappa.b inducing factor Download PDF

Info

Publication number
CA2404688C
CA2404688C CA2404688A CA2404688A CA2404688C CA 2404688 C CA2404688 C CA 2404688C CA 2404688 A CA2404688 A CA 2404688A CA 2404688 A CA2404688 A CA 2404688A CA 2404688 C CA2404688 C CA 2404688C
Authority
CA
Canada
Prior art keywords
nfif
expression
disease
polypeptide
regulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2404688A
Other languages
English (en)
French (fr)
Other versions
CA2404688A1 (en
Inventor
June Kaplow
Thomas Haws
Marie Rosier
Patrice Denefle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0018307.9A external-priority patent/GB0018307D0/en
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of CA2404688A1 publication Critical patent/CA2404688A1/en
Application granted granted Critical
Publication of CA2404688C publication Critical patent/CA2404688C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2404688A 2000-03-31 2001-04-02 Nuclear factor .kappa.b inducing factor Expired - Fee Related CA2404688C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19390500P 2000-03-31 2000-03-31
US60/193,905 2000-03-31
GB0018307.9 2000-07-26
GBGB0018307.9A GB0018307D0 (en) 2000-07-26 2000-07-26 Polypeptides
PCT/US2001/010719 WO2001074900A2 (en) 2000-03-31 2001-04-02 Nuclear factor kb inducing factor

Publications (2)

Publication Number Publication Date
CA2404688A1 CA2404688A1 (en) 2001-10-11
CA2404688C true CA2404688C (en) 2012-07-31

Family

ID=26244722

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2404688A Expired - Fee Related CA2404688C (en) 2000-03-31 2001-04-02 Nuclear factor .kappa.b inducing factor

Country Status (14)

Country Link
EP (1) EP1290023B1 (enExample)
JP (1) JP4750999B2 (enExample)
KR (1) KR100811571B1 (enExample)
AT (1) ATE486089T1 (enExample)
AU (1) AU4793101A (enExample)
CA (1) CA2404688C (enExample)
DE (1) DE60143354D1 (enExample)
DK (1) DK1290023T3 (enExample)
IL (3) IL151987A0 (enExample)
MX (1) MXPA02009481A (enExample)
NO (1) NO331972B1 (enExample)
NZ (1) NZ521786A (enExample)
PT (1) PT1290023E (enExample)
WO (1) WO2001074900A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117534753B (zh) * 2023-12-07 2024-05-10 北京博奥森生物技术有限公司 一种诱导高性能NF-κB多克隆抗体多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486053T3 (de) 1983-10-20 2004-01-08 The Research Foundation Of State University Of New York Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS.
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1992015680A1 (en) 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
WO1993008845A1 (en) 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
AU687736B2 (en) 1992-05-11 1998-03-05 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
EP0651805B1 (en) 1992-07-17 2006-12-13 Dana Farber Cancer Institute Method of intracellular binding of target molecules
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2706486B1 (fr) 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
ES2310924T3 (es) 1993-07-13 2009-01-16 Centelion Vectores adenovirales defectivos y utilizacion en terapia genica.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
WO1997037020A1 (en) * 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US6235512B1 (en) * 1997-07-01 2001-05-22 Tularik Inc. IKK-α proteins, nucleic acids and methods
US6132964A (en) * 1998-02-06 2000-10-17 Incyte Pharmaceuticals, Inc. Hydrolase enzymes
AU4187499A (en) * 1998-05-14 1999-11-29 Chiron Corporation Human genes and gene expression products v
GB9814036D0 (en) * 1998-06-29 1998-08-26 Univ Dundee Materials and methods relating to the induction of apoptosis in target cells
US6077672A (en) * 1998-08-28 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of TRADD expression
CN1302897A (zh) * 1999-10-28 2001-07-11 上海博容基因开发有限公司 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1358347A2 (en) * 2000-04-05 2003-11-05 Incyte Genomics, Inc. Genes expressed in foam cell differentiation
EP1358349A2 (en) * 2000-06-05 2003-11-05 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Also Published As

Publication number Publication date
IL151987A (en) 2010-12-30
AU4793101A (en) 2001-10-15
HK1053312A1 (en) 2003-10-17
DK1290023T3 (da) 2011-02-14
EP1290023A2 (en) 2003-03-12
KR100811571B1 (ko) 2008-03-10
IL151987A0 (en) 2003-04-10
NO331972B1 (no) 2012-05-14
JP2003529360A (ja) 2003-10-07
KR20020087459A (ko) 2002-11-22
WO2001074900A9 (en) 2003-03-06
CA2404688A1 (en) 2001-10-11
JP4750999B2 (ja) 2011-08-17
WO2001074900A3 (en) 2002-05-02
WO2001074900A2 (en) 2001-10-11
PT1290023E (pt) 2011-01-05
NO20024656D0 (no) 2002-09-27
IL198132A0 (en) 2011-08-01
EP1290023B1 (en) 2010-10-27
MXPA02009481A (es) 2004-05-14
NZ521786A (en) 2004-07-30
NO20024656L (no) 2002-11-28
DE60143354D1 (de) 2010-12-09
ATE486089T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
US6300484B1 (en) DNA encoding DP. 75 and a process for its use
EP1217067A2 (en) Connective tissue growth factor-2
US20020048577A1 (en) Methods and devices to modulate the wound response
US7329741B2 (en) Polynucleotides that hybridize to DP-75 and their use
JPH1175873A (ja) 新規化合物
US8623831B2 (en) Nuclear factor κB inducing factor
CA2404688C (en) Nuclear factor .kappa.b inducing factor
AU2001247931B2 (en) Nuclear factor kB inducing factor
AU2001247931A1 (en) Nuclear factor kB inducing factor
ZA200207767B (en) Nuclear factor kB inducing factor.
CA2372803A1 (en) Variants of traf2 which act as an inhibitor of tnf-alpha (tnf .alpha.) signaling pathway
HK1053312B (en) Nuclear factor kb inducing factor
WO2000056756A2 (en) Prolactin regulatory element binding protein and uses thereof
US6258557B1 (en) Smooth muscle cell LIM promoter
JPH11206391A (ja) ヒトｌｉｇ−１相同体（ｈｌｉｇ−１）
US7332593B2 (en) Variants of TRAF2 which act as an inhibitor of TNF-alpha (TNFα) signaling pathway
WO2000076456A2 (en) Modulators of fibrosis
WO2002095008A2 (en) Methods of modulating surfactant phospholipid production
WO2001012126A2 (en) Cardiomyocyte regeneration
WO1997033900A1 (en) E2a-binding protein

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160404